Antitumor 1-nitroacridine derivative C-1748, induces apoptosis, necrosis or senescence in human colon carcinoma HCT8 and HT29 cells

Biochemical Pharmacology

Volumn 79, Issue 9, 2010, Pages 1231-1241

  Augustin, Ewa ^a   Moś Rompa, Anna ^a   Nowak Ziatyk, Dorota ^a   Konopa, Jerzy ^a  

^a GDANSK UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Apoptosis; C 1748; Necrosis; Reactive oxygen species (ROS); Senescence

Indexed keywords

9 (2' HYDROXYETHYLAMINO) 4 METHYL 1 NITROACRIDINE; ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; BETA GALACTOSIDASE; C 1748; CASPASE 3; CELL DNA; MELATONIN; PHOSPHATIDYLSERINE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL DESTRUCTION; CARCINOMA CELL; CELL AGING; CELL CYCLE G1 PHASE; CELL DEATH; CELL PH; CELL POPULATION; CELL STRAIN HT29; CELL STRUCTURE; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXICITY; DIPLOIDY; DNA CONTENT; DNA STRAND BREAKAGE; DRUG STRUCTURE; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; SENESCENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MOLECULAR STRUCTURE; NECROSIS; NITRACRINE;

EID: 77649182247     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.12.012     Document Type: Article

References (32)

1. 2O. Materia Medica Polona 8 (1976) 237-242
2. Gniazdowski M., and Szmigiero L. Nitracrine and its congeners-an overview. Gen Pharmacol 26 (1995) 473-481
3. Bratkowska-Seniów B., Dziedzic J., Fengler I., Steuden W., Szymaniec S., and Wysocka M. Morphologic blood pathern in patients treated with Ledakrin. Materia Medica Polona 8 (1976) 295-301
4. Kwaśniewska-Rokocińska C., Świe{ogonek}cicki J., and Drosik K. Preliminary observations on the Ledakrin effects in treatment of patients with lung carcinoma. Materia Medica Polona 8 (1976) 289-295
5. Chen Y., Ashok B.T., Venkata P., Garikapaty V.P.S., Liu X., Szostek A., et al. Pre-clinical studies of 1-nitroacridine derivatives: effective anti-tumor agents for prostate cancer. Proc Am Assoc Cancer Res 43 (2002) 77
6. Tadi K., Ashok B.T., Chen Y., Banerjee D., Wysocka-Skrzela B., Konopa J., et al. Pre-clinical evaluation of 1-nitroacridine derived chemotherapeutic agent that has preferential cytotoxic activity towards prostate cancer. Cancer Biol Ther 6 (2007) 1632-1637
7. Ashok B.T., Tadi K., Garikapaty V.P.S., Chen Y., Huang Q., Banerjee D., et al. Pre-clinical toxicological evaluation of a putative prostate cancer specific 1-nitroacridine derivative in rodent. Anti-Cancer Drugs 18 (2007) 87-94
8. Ashok B.T., Tadi K., Banerjee D., Konopa J., Iatropoulos M., and Tiwari R.K. Pre-clinical toxicology and pathology of 9-(2′-hydroxyethylamino)-4-methyl-1-nitroacridine (C-1748), a novel anti-cancer agent in male Beagle dogs. Life Sci 79 (2006) 1334-1342
9. Narayanan R., Tiwari P., Inos D., and Ashok B.T. Comparative analysis of mutagenic potency of 1-nitroacridine derivatives. Life Sci 77 (2005) 2312-2323
10. Konopa J., Wysocka-Skrzela B., Szostek A., and Tiwari R. Potent antitumor 4-substituted-1-nitroacridines DNA crosslinking agents. Proc EORTC-NCI-AACR. Boston (2003) 66
11. Konopa J., Pawlak J., and Pawlak K. The mode of action of cytotoxic and antitumor 1-nitroacridines. III. In vivo interstrand crosslinking of DNA of mammalian or bacterial cells by 1-nitroacridines. Chem Biol Interact 43 (1983) 175-197
12. Pawlak K., Pawlak J., and Konopa J. Cytotoxic and antitumor activity of 1-nitroacridines as an aftereffect of their interstrand DNA cross-linking. Cancer Res 44 (1984) 4289-4296
13. Szostek A., Wysocka-Skrzela B., Tiwari R.K., and Konopa J. Interstrand crosslinking of DNA in tumor cells by a new group of antitumor 1-nitroacridines. Int J Cancer 13 (2002) 441
14. Schmitt C.A. Cellular senescence and cancer treatment. Biochim Biophys Acta 1775 (2007) 5-20
15. Gewirtz D.A., Holt S.E., and Elmore L.W. Accelarated senescence: an emerging role in tumor cell response to chemotherapy and radiation. Biochem Pharmacol 76 (2008) 947-957
16. Campisi J., and d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 8 (2007) 729-740
17. Hattangadi D.K., DeMasters G.A., Walker D.T., Jones K.R., Di X., Newsham I.F., et al. Influence of p53 and caspase 3 activity on cell death and senescence in response to methotrexate in the breast tumor cell. Biochem Pharmacol 68 (2004) 1699-1708
18. Roberson R.S., Kussick S.J., Valeries E., Chen S.Y., and Wu D.Y. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells in human lung cancers. Cancer Res 65 (2005) 2795-2803
19. Bhuyan K., Smith K.S., Adams E.G., Petzold G.L., and Mc Govren J.P. Lethality, DNA alkylation and cell cycle effects of adozelesin (U-73975) on rodent and human cells. Cancer Res 52 (1992) 5687-5692
20. Augustin E., Moś-Rompa A., Skwarska A., Witkowski J.M., and Konopa J. Induction of G2/M phase agrest and apoptosis of human leukemia Wells by potent antitumor triazoloacridinone C-1305. Biochem Pharmacol 72 (2006) 1668-1679
21. Ly J.D., Grubb D.R., and Lawen A. The mitochondrial membrane potential (deltapsi(m)) in apoptosis. Apoptosis 8 (2003) 116-128
22. Janicke R.U., Sprengart M.L., Wati M.R., and Porter A.G. Emerging role of caspase-3 in apoptosis. Cell Death Differ 6 (1999) 99-104
23. Yang S., Zhou Q., and Yang X. Caspase-3 status is a determinant of differential responses to genistein between MD-MB-231 and MCF-7 breast cancer cells. Biochim Biophys Acta 1773 (2007) 903-911
24. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., et al. A biomarker that identifies senescent human cells in culture and aging skin in vivo. Proc Natl Acad Sci USA 92 (1995) 9363-9367
25. Kovacic P., and Osuna J.A. Mechanisms of anti-cancer agents: emphasis on oxidative stress and electron transfer. Curr Pharm Des 6 (2000) 277-309
26. Krysko D.V., Berghe T.V., D'Herde K., and Vandenabeele P. Apoptosis and necrosis: detection, discrimination and phagocytosis. Methods 44 (2008) 205-221
27. Rello S., Stockert J.C., Moreno V., Gamez A., Pacheco M., Juarranz A., et al. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 10 (2005) 201-208
28. Galluzzi L., Maiuri M.C., Vitale I., Zischka H., Castedo M., Zitvogel L., et al. Cell death modalities: classification and pathophysiological implications. Cell Death Differ 14 (2007) 1237-1266
29. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., et al. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144 (1999) 281-292
30. Kim J.S., He L., and Lemasters J.J. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 304 (2003) 463-470
31. Gorlewska K., Mazerska Z., Sowiński P., and Konopa J. Products of metabolic activation of the antitumor drug Ledakrin (Nitracrine) in vitro. Chemical Res Toxicol 14 (2001) 1-10
32. Di X., Shiu R.P., Newsham I.F., and Gewirtz D.A. Apoptosis, autophagy, accelerated senescence and reactive oxygen in response of human breast tumor cells to Adriamycin. Biochem Pharmacol 77 (2009) 1139-1150